Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform [0.03%]
利用杂交瘤到噬菌体到酵母平台筛选得到的靶向PD-1和PD-L1的通用型轻链双特异性抗体
Peipei Liu,Chunyin Gu,Xiaodan Cao et al.
Peipei Liu et al.
Background: Therapeutic antibody drugs targeting the PD-1 pathway are generally characterized by relatively low response rates and susceptibility to drug resistance during clinical application. Therefore, there is an urge...
Yuan Cheng,Huu Thuy Trang Duong,Qingyan Hu et al.
Yuan Cheng et al.
The development of lyophilized protein drug products is a critical and complex task in the pharmaceutical industry, requiring a comprehensive understanding of the myriad of factors affecting product quality, stability, and the efficiency an...
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications [0.03%]
适合基础研究和治疗应用的人源化抗CD11d单克隆抗体
Eoin N Blythe,Christy Barreira,Corby Fink et al.
Eoin N Blythe et al.
Background: Immunomodulatory agents targeting the CD11d/CD18 integrin are in development for the treatment of several pathophysiologies including neurotrauma, sepsis, and atherosclerosis. Murine anti-human CD11d therapeut...
A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency [0.03%]
一种用于嵌合抗原受体慢病毒载体功效的工艺评估的生物发光报告基因检测方法
Julia K Gilden,Pete Stecha,Jim Hartnett et al.
Julia K Gilden et al.
Background: Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunotherapy, wherein T cells are genetically modified to recognize and attack cancer cells. Delivery of the CAR gene is...
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma [0.03%]
导向性蛋白质工程鉴定出一种人TIM-4阻断型抗体，可增强小鼠结肠癌中检点抑制的抗肿瘤反应
Karla K Frietze,Kamala Anumukonda,Laura Padula et al.
Karla K Frietze et al.
Background: T-cell immunoglobulin and mucin domain containing molecule-4 (TIM-4) is a scavenger receptor best known for its role in recognizing dying cells. TIM-4 orchestrates phagocytosis allowing for cellular clearance ...
Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening [0.03%]
利用高通量分析和自动化技术快速开发高浓度单克隆抗体制剂：集成了辅料相容性和粘度筛选
Lun Xin,Lan Lan,Mourad Mellal et al.
Lun Xin et al.
Background: Formulation screening is essential to experimentally balance stability and viscosity in high-concentration mAb formulations. We developed a high-throughput approach with automated sample preparation and analyt...
Yanfeng Zhang,Francisca M Acosta,Jean X Jiang
Yanfeng Zhang
Connexin 43 (Cx43) protein forms hemichannels (connexons) and gap junctions, with hemichannels consisting of six Cx43 molecules and gap junctions formed by two hemichannels. While gap junctions are prevalent in organs like the heart and liv...
The process using a synthetic library that generates multiple diverse human single domain antibodies [0.03%]
利用合成文库生成多种多样的人类单结构域抗体的方法
Mark A Tornetta,Brian P Whitaker,Olivia M Cantwell et al.
Mark A Tornetta et al.
Background: Single domain antibodies (sdAbs) possess unique characteristics that make them highly effective for developing complex therapeutics. Methods: ...
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains [0.03%]
一种基于人工智能的抗体发现平台可识别针对多种SARS-CoV-2毒株的新颖、多样且具有药理活性的治疗性抗体
Cristina Moldovan Loomis,Thomas Lahlali,Danielle Van Citters et al.
Cristina Moldovan Loomis et al.
Background: We are entering a new era of antibody discovery and optimization where machine learning (ML) processes will become indispensable for the design and development of therapeutics. ...
FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization [0.03%]
FcRider：一种具有内在佐剂活性的重组免疫纳米颗粒用于混合免疫接种
Changchuin Mao,Karen Eberle,Xiaojie Chen et al.
Changchuin Mao et al.
Active immunization (vaccination) induces long-lasting immunity with memory, which takes weeks to months to develop. Passive immunization (transfer of neutralizing antibodies) provides immediate protection, yet with high cost and effects be...